Literature DB >> 11323786

Respiratory diseases caused by occupational exposure to 1,5-naphthalene-diisocyanate (NDI): Results of workplace-related challenge tests and antibody analyses.

X Baur1, Z Chen, B Marczynski.   

Abstract

BACKGROUND: 1,5-naphthalene-diisocyanate (NDI) is an aromatic diisocyanate with a very low vapor pressure which is mainly used in the automotive industry.
METHODS: In the present study we described five cases with workplace-related asthma and one case with extrinsic allergic alveolitis associated with pulmonary hemorrhage after NDI exposure.
RESULTS: Corresponding to case histories, extrinsic alveolitis on asthmatic reactions in three subjects and a rhinitis reaction in one patient could be reproduced by inhalative challenge tests to NDI at a concentration of 10 ppb. Preliminary IgE and IgG antibody analyses in patients' sera did not produce significantly positive results.
CONCLUSIONS: According to the outcome of our tests and in comparison with several other studies, we conclude that NDI should be classified as potent airway-sensitizing substance. Improved workplace conditions and decrease in threshold limit values should therefore be recommended.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323786     DOI: 10.1002/ajim.1027

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  3 in total

1.  Biological monitoring of exposure to 1,5-naphthalene diisocyanate and 4,4'-methylenediphenyl diisocyanate.

Authors:  C J Sennbro; C H Lindh; C Mattsson; B A G Jönsson; H Tinnerberg
Journal:  Int Arch Occup Environ Health       Date:  2006-02-28       Impact factor: 3.015

2.  Is specific IgE antibody analysis feasible for the diagnosis of methylenediphenyl diisocyanate-induced occupational asthma?

Authors:  Lygia Therese Budnik; Alexandra M Preisser; Hjalmar Permentier; Xaver Baur
Journal:  Int Arch Occup Environ Health       Date:  2012-04-28       Impact factor: 3.015

3.  Bronchial asthma and COPD due to irritants in the workplace - an evidence-based approach.

Authors:  Xaver Baur; Prudence Bakehe; Henning Vellguth
Journal:  J Occup Med Toxicol       Date:  2012-09-26       Impact factor: 2.646

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.